New research finds people sleeping less than six hours a night were much more prone to develop a pre-diabetic condition called incident-impaired fasting glycemia, according to Science Daily.
The likelihood was three times as great as people sleeping an average of six to eight hours nightly.
IFG, which entails poor glucose regulation, can be a precursor to type 2 diabetes as well as heart disease and stroke.
The (more…)
A new analysis of diabetes medications Avandia (rosiglitazone) and Actos (pioglitazone) revealed that the risk of heart attack and/or heart failure, or death were the same, approximately 4%. The study has been published in the latest issue of Circulation: Cardiovascular Quality and Outcomes , an American Heart Association journal.
Takeda Pharmacuetical Co. makes Actos, while GlaxoSmithKline (GSK) makes Avandia. (more…)
New research asserts that pioglitazone (Actos) is as much a cardiovascular risk as rosiglitazone (Avandia).
Published in the journal Circulation‚ the study found that patients who take either drug are at 4 percent higher risk of heart attack‚ heart failure‚ or death. Rosiglitazone is currently under consideration to be taken off the market by the U.S. Food and Drug Administration‚ or to be placed under stronger prescribing restrictions. The (more…)
TUESDAY, Aug. 24 (HealthDay News) — A new study finds that the risk of heart attacks or death after taking the glucose-lowering diabetes drugs Avandia and Actos are about the same.
This is a direct contradiction to numerous other studies that found that the risk was elevated for Avandia (rosiglitazone) but not for Actos (pioglitazone). The findings are, however, in line with some other previous studies, further muddying (more…)